BioNTech Investor Day Presentation Deck

2 Variant-adapted vaccines Omicron-containing modified-variant vaccine summary Neutralizing responses for Omicron-containing vaccines are consistent with regulatory criteria: Simple superiority for GMR and non-inferiority for sero response (monovalent and bivalent vaccines) "Super" superiority for GMR (monovalent vaccines) ● Internal data. Reactogenicity profile of variant vaccines overall similar to prototype BNT162b2 vaccine [DAN Pandemic prep. CAR Pfizer BIONTECH 72

View entire presentation